Valuation: Savara Inc.

Market Cap 1.24B 1.11B 1.02B 928M 1.73B 117B 1.76B 12.27B 4.87B 61.49B 4.64B 4.54B 195B P/E 2026 *
-8.05x
P/E 2027 * -12.5x
Enterprise Value 769M 690M 637M 578M 1.08B 73.04B 1.09B 7.64B 3.03B 38.28B 2.89B 2.82B 121B EV / Sales 2026 *
428x
EV / Sales 2027 * 11.4x
Free-Float
97.45%
Yield 2026 *
-
Yield 2027 * -
1 day-0.10%
1 week+3.21%
Current month-6.59%
1 month-4.93%
3 months-9.57%
6 months-3.99%
Current year-20.07%
1 week 4.13
Extreme 4.13
4.9
1 month 4.13
Extreme 4.13
5.24
Current year 4.13
Extreme 4.13
6.49
1 year 3.86
Extreme 3.86
7
3 years 1.89
Extreme 1.89
7
5 years 1.02
Extreme 1.02
7
10 years 0.69
Extreme 0.69
17.19
Manager TitleAgeSince
Chief Executive Officer 56 30/11/2020
Director of Finance/CFO 57 14/07/2026
Chief Tech/Sci/R&D Officer 56 30/11/2023
Director TitleAgeSince
Director/Board Member 59 31/01/2009
Director/Board Member 77 30/09/2010
Director/Board Member 73 30/09/2013
Date Insider Type Main position Quantity % Market Cap. Importance
24/09/26 Tax

Executive/Senior Manager

-29,323 0.0143%
15/07/26 Free

Chief Financial Officer

105,000 0.0512%
18/03/26 Exercice

Chief Financial Officer

850,254 0.4179%
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%+3.21%+9.29%+31.33% 1.24B
-3.10%-4.19%+32.67%+59.47% 63.48B
+2.30%+1.70%+12.30%+82.90% 54.55B
-0.28%+1.12%+10.59%+102.44% 53.59B
+2.77%+1.74%+29.02%+58.86% 44.75B
+2.44%-4.34%+16.68%+98.11% 41.62B
-0.59%-4.66%+218.43%+909.43% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+18.30%+31.53%+84.52%+73.08% 26.7B
+3.72%-6.23%+26.01%-8.28% 23.36B
Average +2.43%-0.86%+45.05%+145.20% 38.17B
Weighted average by Cap. +1.71%-1.26%+45.21%+157.33%

Financials

2026 *2027 *
Net sales 1.8M 1.61M 1.49M 1.35M 2.52M 171M 2.55M 17.84M 7.08M 89.37M 6.74M 6.59M 283M 79.65M 71.48M 66M 59.85M 112M 7.57B 113M 791M 314M 3.97B 299M 293M 12.57B
Net income -151M -135M -125M -113M -212M -14.33B -214M -1.5B -595M -7.51B -566M -554M -23.82B -94.11M -84.47M -77.99M -70.73M -132M -8.94B -134M -935M -371M -4.69B -353M -346M -14.86B
Net Debt -466M -418M -386M -350M -655M -44.28B -663M -4.63B -1.84B -23.21B -1.75B -1.71B -73.6B -329M -295M -272M -247M -461M -31.2B -467M -3.26B -1.3B -16.36B -1.23B -1.21B -51.87B
Projected Income Statement - Annual - Savara Inc.
Logo Savara Inc.
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
70
Date Price Change Volume
28/10/26 US$4.820 -0.82% 81,939
27/10/26 US$4.860 +7.52% 3,591,282
26/10/26 US$4.520 +7.11% 3,449,003
23/10/26 US$4.220 -7.05% 2,828,603
22/10/26 US$4.540 -2.78% 2,710,107
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Savara Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.860USD
Average target price
11.06USD
Spread / Average Target
+127.48%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Savara Inc.
  1. Stock Market
  2. Stocks
  3. SVRA Stock